Research programme: CD74-targeted cancer therapeutics - Immunomedics

Drug Profile

Research programme: CD74-targeted cancer therapeutics - Immunomedics

Alternative Names: 20-(74)-(74); 20-74-74; 74-(20)-(20); 74-20-20; Anti-CD74 antibodies - Immunomedics; CD74-RNase

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action Invariant chain inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 05 Apr 2011 Preclinical pharmacodynamics data presented at the American Association for Cancer Research (AACR-2011)
  • 28 Nov 2003 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top